Contents

Search

ertugliflozin/metformin (Segluromet)

Indications: - treatment of diabetes mellitus type 2 Dosage: - BID oral dosing Tabs: ertugliflozin/metformin - 2.5 mg/500 mg, 2.5 mg/1000 mg, 7.5 mg/500 mg, 7.5 mg/1000 mg.

Interactions

drug adverse effects of hypoglycemic agents

General

hypoglycemic combination

References

  1. Busko M FDA Approves SGLT2 Inhibitor Ertugliflozin for Type 2 Diabetes Medscape - Dec 21, 2017. https://www.medscape.com/viewarticle/890446